Literature DB >> 11716989

Genetics of menopause-associated diseases.

F Massart1, J Y Reginster, M L Brandi.   

Abstract

Menopause is the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. It is estimated that perhaps 50 million women worldwide will go into menopause annually. Atherosclerotic cardiovascular disease, osteoporotic fractures and Alzheimer's dementia are common chronic disorders after menopause, representing major health problems in most developed countries. Apart from being influenced by environmental factors, these chronic disorders recognize a strong genetic component, and there are now considerable clinic evidences that these disorders are related to low hormonal milieu of postmenopausal women. Here, we review up-to-date available data suggesting that genetic variation may contribute to higher susceptibility to four sporadic chronic syndromes such as osteoporosis (OP), osteoarthritis (OA), Alzheimer's disease (AD) and coronary artery disease (CAD). For these four syndromes candidate genes that today appear as major loci in genetic susceptibility encode for proteins specific of a given system, as the vitamin D receptor (VDR) gene for the skeleton and, therefore, OP or angiotensin converting enzyme (ACE) for the cardiovascular system and, therefore, CAD. The investigation of gene polymorphisms in various pathological conditions typical of postmenopause offer an explanation not only of their genetic inheritance but also of their co-segregation in given individuals. In this view, it may be possible to identify a common set of genes whose variants contribute to a common genetic background for these different disorders. Ideal candidates appear genes of the estrogen response cascade [i.e. estrogen receptor (ERs), enzymes involved in estrogen metabolism or co-activators and co-inhibitors]. All together this information may represent the basis both for future recognition of individuals at risk and for the pharmacogenetic driving of drug responsiveness.

Entities:  

Mesh:

Year:  2001        PMID: 11716989     DOI: 10.1016/s0378-5122(01)00283-3

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  8 in total

1.  Genetics of the bone response to bisphosphonate treatments.

Authors:  Francesco Massart; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

2.  Indications on the use of vitamin D and vitamin D metabolites in clinical phenotypes.

Authors:  M L Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2010-09

3.  Bone mass pharmacogenetics and ethnic health implications.

Authors:  Francesco Massart; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2007-05

4.  Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome.

Authors:  Julia Pinsonneault; Wolfgang Sadée
Journal:  AAPS PharmSci       Date:  2003-11-05

Review 5.  Review of Prospects of Biological Fluid Biomarkers in Osteoarthritis.

Authors:  Lich Thi Nguyen; Ashish Ranjan Sharma; Chiranjib Chakraborty; Balaji Saibaba; Moo-Eob Ahn; Sang-Soo Lee
Journal:  Int J Mol Sci       Date:  2017-03-12       Impact factor: 5.923

Review 6.  Sex Differences in Biological Systems and the Conundrum of Menopause: Potential Commonalities in Post-Menopausal Disease Mechanisms.

Authors:  David A Hart
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

7.  Age-specific effects of estrogen receptors' polymorphisms on the bone traits in healthy fertile women: the BONTURNO study.

Authors:  Francesco Massart; Francesca Marini; Gerolamo Bianchi; Salvatore Minisola; Giovanni Luisetto; Antonella Pirazzoli; Sara Salvi; Dino Micheli; Laura Masi; Maria Luisa Brandi
Journal:  Reprod Biol Endocrinol       Date:  2009-04-22       Impact factor: 5.211

8.  Association of Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms with Osteoporotic Vertebral Compression Fractures (OVCFs) in Postmenopausal Women.

Authors:  Jung Oh Kim; Soo Hong Han; Yeon Ho Lee; Tae Keun Ahn; Jae Joon Lim; Young Sun Chung; Dong Eun Shin; Woo Sik Lee; In Bo Han; Nam Keun Kim
Journal:  Int J Mol Sci       Date:  2016-12-09       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.